<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="50188">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01791829</url>
  </required_header>
  <id_info>
    <org_study_id>OCOG-2012-LUMINA</org_study_id>
    <nct_id>NCT01791829</nct_id>
  </id_info>
  <brief_title>A Prospective Cohort Study Evaluating Risk of Local Recurrence Following Breast Conserving Surgery and Endocrine Therapy in Low Risk Luminal A Breast Cancer</brief_title>
  <acronym>LUMINA</acronym>
  <official_title>A Prospective Cohort Study Evaluating Risk of Local Recurrence Following Breast Conserving Surgery and Endocrine Therapy in Low Risk Luminal A Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ontario Clinical Oncology Group (OCOG)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>British Columbia Cancer Agency</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ontario Clinical Oncology Group (OCOG)</source>
  <oversight_info>
    <authority>Canada: Health Canada</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicentre, single-arm prospective cohort study evaluating risk of ipsilateral
      breast tumour recurrence(IBTR) following breast conserving surgery (BCS) in a group of women
      postulated to be at low risk for recurrence. Women with luminal A breast cancer determined
      by immunohistochemical(IHC) and other low risk clinical testing (see below) will be treated
      with endocrine therapy (tamoxifen or aromatase inhibitor) for five years and will not be
      treated with breast irradiation (BI). Subjects will be followed for 10 years and will be
      assessed for recurrent disease, new primary cancer and survival.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The independent prognostic ability of the luminal A subtype has been demonstrated in two
      retrospective analyses of prospective trials and suggests that luminal A combined with other
      known clinical prognostic factors could be used to select patients treated with BCS at very
      low risk for IBTR who could avoid BI.  Given that using intrinsic subtyping combined with
      other clinical factors to identify women who could avoid BI would be a major change in
      clinical practice, we propose that a prospective study is necessary to confirm that such an
      approach can accurately identify a group of women at very low risk for IBTR following BCS.

      We anticipate that the risk of IBTR in the low risk group is likely to be lower than that
      observed in previous trials (predicted to be &lt; 5% at 5 years and &lt; 10% at 10 years) for
      several reasons: first, our selection criteria (node negative, luminal A, &gt; or = 60 years,
      tumours &lt; or = 2cm, excision margin &gt; or = 2mm post-BCS, absence of lobular cancers,
      extensive intraductal component and lymphovascular invasion) are  more restrictive than in
      previous trials and second, the risks of IBTR are steadily decreasing over time due to
      improvements in mammographic screening, pre-op staging, tumour localization, and surgical
      practice. The expected low failure rates are unlikely to warrant the use of radiation.

      A prospective cohort study was identified as the most appropriate and efficient design as
      our primary hypothesis is that a group of patients at very low risk of IBTR can be
      identified. A randomized trial could address the effectiveness of radiation in such a cohort
      of patients, but would require a much larger sample size to detect very small differences,
      which would not be clinically meaningful. During the conduct of this trial it is anticipated
      that patients who do not meet study criteria or who decline study enrollment, will continue
      to receive BI after BCS.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2013</start_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Ipsilateral Breast Tumour Recurrence (IBTR)</measure>
    <time_frame>5 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>The primary outcome is IBTR defined as recurrent invasive or in-situ cancer in the ipsilateral breast during follow-up. Histological evidence of recurrence will be required. All recurrences will be reviewed by a central adjudication committee.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recurrence Free interval (RFI)</measure>
    <time_frame>5 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Recurrence free interval (RFI) defined as time from registration to time of documented recurrent disease (ipsilateral breast, regional or distant)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-free survival (EFS)</measure>
    <time_frame>5 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Event-free survival (EFS) defined as the time from registration to the time of documented IBTR, regional (ipsilateral axilla, supraclavicular or internal mammary nodes), distant recurrence (contralateral lymph nodes, bone, liver, lung, brain, etc.), contralateral breast cancer, new primary cancer or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>5 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Overall survival (OS) defined as time from registration to death of any cause</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Luminal A with other Clinical Criteria</arm_group_label>
    <description>BCS postulated to be at low risk for IBTR following Endocrine Therapy</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Specimens will be used to determine Ki67 status by IHC and subsequent testing for DNA/RNA.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        This is a multicentre, single-arm prospective cohort study evaluating risk of IBTR
        following BCS in a group of women postulated to be at low risk for recurrence. Subjects
        will be followed for 10 years and will be assessed for recurrent disease, new primary
        cancer and survival. The primary outcome is IBTR
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Female patient &gt; or = 60 years of age with a new diagnosis of invasive carcinoma of
             the breast (ductal, tubular or mucinous only) with primary tumour &lt;  or =2cm on
             microscopic exam, with no evidence of metastatic disease;

          2. ER positive and PR positive and HER2 negative (as determined by an accredited
             laboratory);

          3. Treated by BCS with microscopically clear resection margins &gt; or = 2mm or no residual
             disease on re-excision;

          4. Negative axillary node involvement determined by sentinel node biopsy or axillary
             node dissection.

        Exclusion Criteria:

          1. Clinical or pathological evidence of T4 disease (i.e. extension to chest wall, skin
             involvement, peau d'orange, or inflammatory breast cancer).

          2. Multifocal or multicentric disease.

          3. Evidence of an extensive intraductal component (defined as a tumour that is composed
             of 25% or more of DCIS and the DCIS extends beyond the gross dimensions of the
             tumour), or disease limited to micro invasion only.

          4. Grade 3 histology.

          5. Evidence of lymphovascular invasion.

          6. Evidence of disease on pre-operative mammogram, aside from primary cancer treated by
             breast conserving surgery.

          7. Bilateral malignancy of the breast (synchronous or metachronous).

          8. Known BRCA 1 or 2 mutations.

          9. History of non-breast cancer malignancies if not disease free for &gt; 5 years and
             considered low risk of recurrence with the exception of treated carcinoma in-situ of
             the cervix, endometrium or colon, melanoma in-situ and basal or squamous cell
             carcinoma of the skin.

         10. Serious non-malignant disease associated with a life expectancy &lt; 10 years.

         11. Inability to be treated with or to tolerate endocrine therapy.

         12. Psychiatric or addictive disorder, which would preclude obtaining informed consent or
             adherence to protocol.

         13. Geographic inaccessibility for follow-up.

         14. Inability to understand or unable to provide written informed consent.

         15. Inability to be registered on study within 12 weeks of the last surgical procedure on
             the breast.

         16. Central testing for Ki67 &gt; 13% consistent with the luminal B subtype
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tim Whelan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ontario Clinical Oncology Group (OCOG)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sally Smith, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>British Columbia Cancer Agency (BCCA)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Luciana Spadafora</last_name>
    <phone>905-527-2299</phone>
    <phone_ext>42655</phone_ext>
    <email>spadafl@mcmaster.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sharon Nason</last_name>
    <phone>905-527-2299</phone>
    <phone_ext>42622</phone_ext>
    <email>nasons@mcmaster.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>BCCA - Centre for the North</name>
      <address>
        <city>Prince George</city>
        <state>British Columbia</state>
        <zip>V2M 7E9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Olson, M.D.</last_name>
      <phone>250-645-7325</phone>
      <email>rolson2@bccancer.bc.ca</email>
    </contact>
    <contact_backup>
      <last_name>Alice Muirhead</last_name>
      <phone>250-645-7300</phone>
      <phone_ext>687522</phone_ext>
      <email>alice.muirhead@bccancer.bc.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Robert Olson, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stacy Miller</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Boris Valev</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>BC Cancer Agency</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <zip>V9R 6V5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sally Smith, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tanya Berrang</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pauline Truong</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Isabelle Vallieres</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elaine S Wai</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Victoria Regional Health Centre</name>
      <address>
        <city>Barrie</city>
        <state>Ontario</state>
        <zip>L4M 6M2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christiaan Stevens, M.D.</last_name>
      <phone>705-728-9090</phone>
      <email>stevensc@rvh.on.ca</email>
    </contact>
    <contact_backup>
      <last_name>Kim Marsh-Gray</last_name>
      <phone>705-728-9090</phone>
      <phone_ext>43340</phone_ext>
      <email>marshk@rvh.on.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Mathew J Follwell, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tiffany Tam, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christiaan Stevens, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Juravinski Cancer Centre</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 1C3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tim Whelan, MD</last_name>
      <phone>905-387-9711</phone>
      <phone_ext>64501</phone_ext>
      <email>tim.whelan@jcc.hhsc.ca</email>
    </contact>
    <investigator>
      <last_name>Tim Whelan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ian S Dayes</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Iwa Kong</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Harold Reiter</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Barbara K Strang</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>James R Wright</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Centre of Southern Ontario at Kingston</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Conrad Falkson, MD</last_name>
      <phone>613-549-6666</phone>
      <phone_ext>4509</phone_ext>
      <email>conrad.falkson@krcc.on.ca</email>
    </contact>
    <contact_backup>
      <last_name>Christine L Maize, BSc.</last_name>
      <phone>613-549-6666</phone>
      <phone_ext>6611</phone_ext>
      <email>christine.maize@krcc.on.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Conrad Falkson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kishore S Thain</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>William MacKillop</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ellen C de Metz</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Grand River Regional Cancer Centre</name>
      <address>
        <city>Kitchener</city>
        <state>Ontario</state>
        <zip>N2G 1G3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ramana M Rachakonda, M.D.</last_name>
      <phone>519-749-4300</phone>
      <phone_ext>5489</phone_ext>
      <email>ramana.rachakonda@grhosp.on.ca</email>
    </contact>
    <contact_backup>
      <last_name>Kristin Krokoszynski</last_name>
      <phone>519-749-4370</phone>
      <phone_ext>2664</phone_ext>
      <email>kristin.krokoszynski@grhosp.on.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Ramana M Rachakonda, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Darin Gopaul, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vasanth Basrur, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sofya Kobeleva, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joda Kuk, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sundeep Shahi</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>R.S. McLaughlin Durham Regional Cancer Centre</name>
      <address>
        <city>Oshawa</city>
        <state>Ontario</state>
        <zip>L1G 2B9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wayne Koll, M.D.</last_name>
      <phone>905-576-8711</phone>
      <phone_ext>3815</phone_ext>
      <email>akoll@lakeridgehealth.on.ca</email>
    </contact>
    <contact_backup>
      <last_name>Edeliza Mendoza, BSc,</last_name>
      <phone>905-576-8711</phone>
      <phone_ext>4297</phone_ext>
      <email>emendoza@lakeridgehealth.on.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Wayne Koll, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Behzad Banihashemi</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Frederick P Dixon</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Medhat El-Mallah</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Orit Freedman</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fawaad Iqbal</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Audrey WY Li</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jimmy Mui</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Donald S Myrehaug</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1Z6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anthony W Fyles, M.D.</last_name>
      <phone>416-946-6522</phone>
      <email>anthony.fyles@rmp.uhn.on.ca</email>
    </contact>
    <contact_backup>
      <last_name>Lea M. Dungao</last_name>
      <phone>416-946-4501</phone>
      <phone_ext>2589</phone_ext>
      <email>lea.dungao@rmp.uhn.on.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Anthony W Fyles, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Caroline Chung</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kathy Han, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fei-Fei Liu, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://www.ocog.ca</url>
  </link>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 24, 2014</lastchanged_date>
  <firstreceived_date>February 12, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Luminal A</keyword>
  <keyword>Ipsilateral Breast Tumour Recurrence</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
